ASA404
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Histologically-proven and Radiologically-confirmed Solid Tumors
Conditions
Histologically-proven and Radiologically-confirmed Solid Tumors
Trial Timeline
Jan 1, 2010 → —
NCT ID
NCT01278849About ASA404
ASA404 is a phase 1 stage product being developed by Novartis for Histologically-proven and Radiologically-confirmed Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT01278849. Target conditions include Histologically-proven and Radiologically-confirmed Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01240642 | Phase 1 | Terminated |
| NCT01278849 | Phase 1 | Terminated |
| NCT01299701 | Phase 1 | Terminated |
| NCT00674102 | Phase 1 | Completed |